Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774900 | 0.91 | TLR8 (0.36) | ESR1ESR2TLR8MAOALIPG | |
| SCHEMBL5575415 | 0.89 | TLR8 (0.36) | ESR1ESR2TLR8MAOALIPG | |
| SCHEMBL3785091 | 0.86 | LTB4R (0.41) | LIPGLTB4RNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3787116 | 0.79 | LIPG (0.40) | LIPGLTB4RSMN1; SMN2MAPT | |
| SCHEMBL12921564 | 0.78 | MAPT (0.34) | NPC1LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL12921568 | 0.78 | MAPT (0.34) | NPC1LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL13446389 | 0.78 | LTB4R (0.42) | LIPGLTB4RNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13410246 | 0.77 | ESR1 (0.32) | ESR1ESR2MAPT | |
| SCHEMBL12921559 | 0.77 | ALOX15 (0.34) | MAPT | |
| SCHEMBL13410145 | 0.76 | ESR1 (0.31) | ESR1ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331550-A1 | THIENOTHIOPHENE DERIVATIVES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-12-30 | — | — | US | claimed |
| US-8329915-B2 | Thienothiophene derivatives | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-12-11 | — | — | US | disclosed |
| US-20100331550-A1 | THIENOTHIOPHENE DERIVATIVES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331550-A1 | THIENOTHIOPHENE DERIVATIVES | TST, TPST2, TH | ESR1 1535/4885ESR2 1268/4885TLR8 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.